NEWS & MEDIA
Featured
ASX News
Telix Pharmaceuticals Enters Strategic Collaboration with Varian Medical Systems for Advanced Prostate Imaging
Melbourne (Australia) and Palo Alto, CA (USA) – 3rd September 2020. Telix announces it has entered into a strategic collaboration...
ASX News
Telix Pharmaceuticals and IRE Elit Enter Distribution Partnership for Prostate Cancer Imaging
Herstal and Fleurus (Belgium) – 1st September 2020. Telix announces distribution agreement with Fleurus-based IRE Elit S.A. to distribute Telix’s...
ASX News
FDA Grants Orphan Drug Designation for TLX102
Melbourne (Australia) – 31st August 2020. Telix announces the FDA has granted ODD for 4-[211At] astato-l-phenylalanine for the treatment of...
ASX News
Half Year Shareholder Update
Melbourne (Australia) – 21st August 2020. Telix Pharmaceuticals Limited Announces Half-year Shareholder Update
ASX News
First patient dosed in renal cancer imaging study in Japan
Melbourne (Australia) – 18th August 2020. Telix announces the first patient has been dosed in a Phase I/II study of...
ASX News
Drug Master File for Glioblastoma Therapy Product Filed with FDA
Melbourne (Australia) and Indianapolis, IN (USA) – 11th August 2020. Telix announces it has submitted a Drug Master File to...
ASX News
Telix H1 2020 Results and Company Update Conference Call
Melbourne (Australia) – 11th August 2020. Telix will hold an investor conference call to present the Company’s H1 2020 financial...
ASX News
Activities Report and Sales Note to Accompany Appendix 4C
Melbourne (Australia) – 27th July 2020. Telix Pharmaceuticals provides its Activities Report and Appendix 4C for the quarter ending 30th...
ASX News
Telix Pharmaceuticals Receives $11.4M R&D Tax Refund
Melbourne (Australia) – 21st July 2020. Telix Pharmaceuticals announces it has received an A$11.4M R&D tax refund in relation to...
ASX News
Telix Pharmaceuticals and RefleXion Medical Enter Strategic Collaboration for Treatment of High-Risk Cancers
Melbourne (Australia) – 8th July 2020. Telix Pharmaceuticals Limited announces it has entered into a strategic collaboration agreement with RefleXion Medical
ASX News
Telix Granted FDA Breakthrough Therapy Designation for Renal Cancer Imaging Product
Melbourne (Australia) – 1st July 2020. Telix announces that the FDA has granted Breakthrough Therapy (BT) designation for Telix’s renal...
Corporate Spotlight
Telix presents IPAX-1 study in glioblastoma treatment at ASCO 2020
25th May 2020 - Clinical Spotlight | Telix Presents the IPAX-1 Study at the American Society of Clinical Oncology (ASCO)